CYDY - CytoDyn posts preliminary results from COVID-19 long-haulers study

CytoDyn ([[CYDY]]) announces preliminary results after unblinding the data from its COVID-19 long-haulers clinical trial.The purpose of the trial was to assess the safety and efficacy of leronlimab administered as weekly subcutaneous injection in subjects experiencing prolonged symptoms (> 12 weeks) of COVID-19.The primary outcome was change from baseline in daily COVID-19-related symptom severity score through Day 56.The company said that once final analysis of the data is completed, it plans to hold discussions with the U.S. FDA regarding the next steps.

For further details see:

CytoDyn posts preliminary results from COVID-19 long-haulers study